STOCK MARKET BSE NSE

Government says recipients of Bharat Biotech jabs are being followed up actively

In the case of Covishield, Bhushan said, recipients are advised to stay at vaccination centres for half an hour and report in case of uneasiness.

Published: 20th January 2021 10:49 AM  |   Last Updated: 20th January 2021 10:49 AM   |  A+A-

A medic vaccinates a healthcare staff with Covishield in Mumbai on Tuesday.

A medic vaccinates a healthcare staff with Covishield in Mumbai on Tuesday. (Photo | PTI)

By Express News Service

NEW DELHI: The Centre on Tuesday said that the key difference between the administration of Covishield and Covaxin is that the first group of recipients are being followed up only “passively” unlike more robust look out for adverse events in the case of the other vaccine. 

Bharat Biotech’s Covaxin is being used in India despite still being under Phase 3 trial, with the drug regulator mandating that the vaccine can only be used in “clinical trial mode”.

ALSO READ: Covaxin being used cautiously in first phase?

To a media query, Union health secretary Rajesh Bhushan said while there is a robust mechanism in place to monitor adverse events following immunisation, there is another difference in the way the recipients are followed up in the case of two vaccines.  

In the case of Covishield, Bhushan said, recipients are advised to stay at vaccination centres for half an hour and report in case of uneasiness.

For Covaxin, recipients are called everyday to check on their health updates. “They are also asked to sign detailed forms on their health status for a week,” Bhushan said. On being asked about who gets to decide on the use of Covishield and Covaxin, he said it was up to the states.

ALSO READ: People with fever, pregnant and breastfeeding women avoid Covaxin - Bharat Biotech

“States decide which vaccine they want. The Centre delivers vaccines to states and then the respective government decides which vaccine centres will get how many vaccines.” India’s active Covid-19 caseload has come down to 2 lakhs with only Kerala and Maharashtra  registering over 50,000 cases, he said.  

Why worry

Covaxin is being used in India despite still being under Phase 3 trial, with the drug regulator mandating that the vaccine can only be used in “clinical trial mode”.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp